comparemela.com

Scientific Retreat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Updated Results from the Phase 1/2 Study of ESSA s Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.

United statesBritish columbiaAndrew laccettiNan hyung hongDavid parkinsonPharma incProstate cancer foundationCancer foundationScientific retreatMetastatic castration resistant prostate cancerFirst in human dose escalation phaseEnz alonePreliminary resultsDose optimization componentFast trackPrivate securities litigation reform act

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

VANCOUVER, Canada and HOUSTON, Texas, Oct. 28, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the

United statesBritish columbiaNan hyung hongVirtual international conference on molecularHealth canadaPharma incProstate cancer foundationCancer foundationScientific retreatInternational conferenceMolecular targetsNan hyungFast trackPrivate securities litigation reform act

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.

United statesBritish columbiaNan hyung hongVirtual international conference on molecularHealth canadaPharma incProstate cancer foundationCancer foundationScientific retreatInternational conferenceMolecular targetsNan hyungFast trackPrivate securities litigation reform actEssa pharma inc

vimarsana © 2020. All Rights Reserved.